In this manuscript, cell surface NCL is proposed as a new targetable protein for NB in pre-clinical models, and it is suggested as a possible future NB marker and an innovative therapeutic cellular target in the clinical setting. This evidence concerns the gene NUCLEOLIN and neuroblastoma.